Get started

MRK

Merck is Flying based on the biased perception..!Merck data shows Molnupiravir will decrease mortality and hospitalization which is a good news, but do not forget it does not mean you do not need COVID-19 Vaccine..! This is only for those who becomes positive for COVID test, while Vaccine is for everyone! While many people debate about their choice of being vaccinated or not, I would like to show other countries example: Australia: No Jab No Pay is an Australian policy initiative which withholds three state payments – Child Care Benefit, the Child Care Rebate and a portion of the fortnightly Family Tax Benefit part A per child – for parents of children under 20 years of age who are not fully immunized or on a recognized catch-up schedule. No Jab No Play is a related policy that disallows unvaccinated children from attending preschool and childcare centres, and imposes fines on childcare centres that admit unvaccinated children. The system allows exemptions for children who cannot be safely vaccinated for medical reasons. As a doctor I respect patients choice, but when it is about public health things will become a little complicated from ethical point of view! I got vaccinated as soon as it becomes possible, and asked all my family members to do so. I want to use this opportunity to ask you to get vaccinated and do not pay attention to misinformation. I published short analysis on MRNA before this news: Best, Moshkelgosha
NYSE:MRKShort
by Moshkelgosha
2
INO What You're Thinking...INO finally broke back above the 786 fib line. Before the last bout of selling, you'll see this level was an area of support for the former penny stock. Now, thanks to some added excitement from delta news (the variant not the airline), INO shares are popping. They also jumped back above the 786 fib. Now the question is, will it rest the 618 fib like it tried to a few weeks ago? "Inovio Pharmaceuticals Inc. (NASDAQ: INO) has steadily climbed for the better part of the last 3 months thanks to recent pipeline progress. In June, the company had expanded its partnership with Advaccine Biopharmaceuticals Suzhou to conduct a Phase 3 segment of a trial called INNOVATE. The goal is to evaluate the safety and efficacy of the company’s INO-4800 in COVID patients. The treatment was already shown to be well tolerated and immunogenic in tested age groups in a Phase 2 study. This month Inovio announced that it and Advaccine received a regulatory allowance for 2 heterologous prime-boost clinical trials in China using INO-4800. “VID-19. If approved, we believe INO-4800 will be well-positioned to serve the vaccine needs of the global community as both a primary and a booster vaccine due to its tolerability, balanced cross-reactive immune responses, and strong thermostability profile that does not require cold or ultra-cold-chain transport,” said Dr. J. Joseph Kim, President, and CEO of INOVIO." Quote Source & Read more on INO: Former Penny Stocks To Watch After Merck’s ( MRK ) Latest FDA Win
NASDAQ:INO
by PennyStocks101
1
BMY Flirting With Historic TerritoryWhen I say "historic" for BMY I'm not talking ATH but the stock's encroaching on an area that has been tested 3 times being rejected each time. This is the 236 fib area using 2016's high as the top anchor. It's been 5 years since BMY traded well above this area. But with the way attention is being placed on immunotherapy stocks, it could be something to keep in mind for BMY longs. " Both Bristol-Myers and Novartis recently gave updates on new FDA updates. Novartis’ NIS793 gained FDA Orphan Drug Designation, while Bristol-Myers’ recent earnings update revealed strong sales figures from its lead cancer drug, Opdivo...B7H3 protein is a checkpoint molecule, which has very recently become a target for cancer treatment. While things are still in the very early stages for B7 molecules, as a whole, early research is also finding new potential for targeted cancer treatments. For instance, Merck’s (NYSE: MRK ) blockbuster drug, Keytruda, and Bristol-Myers’ YERVOY treatments target the same checkpoint inhibitors that are part of the B7 family (PD-1/PD-L1 and CTLA-4/CD80). They’ve also both demonstrated a clear survival benefit when it comes to immune-oncology treatment ." Quote Source & Read More: Hot Biotech Stocks To Watch After Sanofi’s Acquisition Of Translate Bio
NYSE:BMY
by PennyStocks101
MRK Testing the upper limits But Can It Make New Highs?MRK is back in this 382-236 fib range with both lining up pretty tightly with the current levels on the chart. 382 is a bit looser and more of a pivot area, for now, that's been a magnet for the stock over the last few weeks. Meanwhile, 236 was tested a few times and MRK was rejected each time. With the last update on Keytruda, it's going to be interesting to see what comes next. "Merck’s (NYSE:MRK) big news on July 27th marked a watershed moment for the company’s cancer treatment, Keytruda. The Food & Drug Administration approved Keytruda for treating patients with high-risk early-stage triple-negative breast cancer (TNBC), in combination with chemotherapy. Following surgery, Keytruda could then continue as a single agent adjuvant. This approval was based on Merck’s Phase 3 KEYNOTE-522 trial....Merck’s (NYSE: MRK) blockbuster drug, Keytruda, and Bristol-Myers’ YERVOY treatments target the same checkpoint inhibitors that are part of the B7 family (PD-1/PD-L1 and CTLA-4/CD80). They’ve also both demonstrated a clear survival benefit when it comes to immune-oncology treatment...This B7H3 protein is a checkpoint molecule, which has very recently become a target for cancer treatment." Quote Source & Read More: Hot Biotech Stocks To Watch After Sanofi’s Acquisition Of Translate Bio
NYSE:MRK
by PennyStocks101
MRK - Merck & Co - WEEKLY Setup - Holding the 200emaI Hate Trading Pharma But... MRK BUYZONE = 74 - 76 Cost Avg Down (CAD) = 72 - 70 1st Target = 79 2nd Target = 82 3rd Target = 86 HODL Target = ATH ______________________________________________________________________________________________________________________ This content is for informational, educational and entertainment purposes only. This is not in any way, shape or form financial or trading advice. Good luck, happy trading and stay chill, 2degreez
NYSE:MRKLong
by UnknownUnicorn7216011
Buy $MRK - NRPicks Feb 07Merck & Co, Inc. provides healthcare solutions worldwide. The company offers treatments for cardiovascular disease, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal infections, fungal infections, insomnia and inflammatory diseases; neuromuscular blocking agents; cholesterol-modifying drugs; and vaginal contraceptive and antibacterial products. Merck is one of the companies that had been selected to develop the vaccine; however, it is still a company with a very high level team of workers and successful products. In terms of its finances, its debt is average relative to industry-competitors, plus it generates enough cash to be able to meet those obligations. Fundamentals: - Growth - 6% estimated growth in net earnings for the next 3 years. - ROE 50.5% VS 17% industry. Technicals: - Price level below SMA 250-200-150 - Williams R% at -78% levels - RSI (36) Oversold -1.5% average upside during the month A correction of 11% was presented from JANUARY 12 to FEBRUARY 5, which stopped at $75.45 support. The correction was presented because the company abandoned the development of the vaccine against COVID, from the support the stock has shown a change of trend. Finally, the technical indicators are favorable and give us a buy signal.
NYSE:MRKLong
by NewroadTrader
1
MRK Technical Analysis 🧙Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, close to 40% of the firm's sales are generated in the United States. If you understand the idea,🎯 press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
NYSE:MRKLong
by trading_as_bus
$MRK ELLIOTWAVESMy current waves on $MRK would love some feedback, this catalyst and original chart was brought up originally by @tomikazi It broke out of the downtrend channel and now is in wave 1. Has a catalyst on Wednesday 1/20/21 PDUFA VII Decision for MRK's Vericiguat: Merck Seeks Approval For Heart Failure Drug Company: Merck & Co., Inc. (NYSE: MRK) Type of Application: NDA Candidate: vericiguat Indication: heart failure Positive ER expected : Merck & Co., Inc.'s earnings, with the lowest EPS estimate coming in at $1.32 and the highest estimate coming in at $1.38. Merck & Co., Inc. reported earnings of $1.16 per share during the same quarter last year, which indicates a positive year over year growth rate of 16.4%. The firm is scheduled to issue its next quarterly earnings report before the market opens on Thursday, February 4th. -Marketbeat
NYSE:MRKLong
by SigCharts
Long Gild - Covid Drug ($MRNA $GSK $INO $SPY $PFE $JNJ $MRK)see full chart at www.tradingview.com Gild Entry $62 area Target 1 $67 Target 2 $71 stoploss $59 Why this play? Trump used Gild's drug as part of his treatment, if he pulls thru with a full recovery. they will probably start pumping the news about this company and it'll finally have enough momentum to move back to the upside. What is Gild? Gilead Sciences, Inc., is an American biopharmaceutical company headquartered in Foster City, California that researches, develops and commercializes drugs. The company focuses primarily on antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi. Notable price upgrades Sep-30-20 Resumed Jefferies Buy $78 Sep-15-20 Upgrade Maxim Group Hold → Buy $88
NASDAQ:GILDLong
by WallSt007
3
Long and hold $GSK ($MRNA $GILD $INO $SPY $PFE $JNJ $MRK)see full chart at www.tradingview.com GSK Entry $39.70 Target 1 $42.45 Target 2 $45.50 Target 3 $48 stoploss 38.70 Why this play? There are 4 general approaches to the Covid vaccine. 1.A "killed" coronavirus that will get recognized as foreign matter in the blood. (Sinovac/Dynavax) 2.Coronavirus proteins themselves, produced industrially in outside cell cultures, which will be recognized as foreign matter in the blood. (GlaxoSmithKline/Sanofi, Novavax) 3.A different virus (human or ape adenovirus, measles, etc) that is engineered to include genetic components coding for the SARS-CoV-2 spike proteins, which causes the body to then produce them. (CanSino, Oxford, J&J, Merck/Themis) 4.DNA or RNA that will be taken up by cells and will cause them to make coronavirus proteins. (Moderna, Innovio, BioNTech/Pfizer) GSK is #2, there is only 1 other big company doing this approach and that is NVAX. We are betting on the fact that if they are successful, they could have super run like NVAX. What is GSk? www.gsk.com GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Merck KGaA; Lyell Immunopharma; CEPI; Innovax and Xiamen University; VBI; Viome; Sanofi SA; CureVac; and research collaboration with Sengenics focusing on immunology. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
NYSE:GSKLong
by WallSt007
Bullish Charts - FDA Grants Orphan Drug Designation for LymphomaMiragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high-unmet medical need. Its four lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous and ocular fibrosis, which is in Phase II clinical trial; MRG-229, which is in preclinical trial for the treatment of idiopathic pulmonary fibrosis; and MRG- 110, an inhibitor of miR-92, a microRNA expressed in endothelial cells, which has completed two Phase I clinical trial for the treatment of heart failure, wound healing, and other ischemic disease in the United States and Japan. Miragen Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado. LATE BREAKING NEWS AFTER HOURS - POSSIBLY A BIG SPIKE IN THE MORNING miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that the Food & Drug Administration (FDA) has granted orphan drug designation to cobomarsen, for the treatment of T-cell lymphoma. DAILY CHART IS BULLISH OBV is Bullish MACD turned up Bullish RSi crossed center line and turned up, Bullish PMO is turning up, Bullish This little stock could spike hard. Best of luck everyone! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
MLong
by HotCharts